In late May, Zhao Hongyan was one of about two dozen in-house lawyers who spoke at a Shanghai conference. Her topic was extremely common for such confabs: dealing with corruption.
However closely her audience listened will be nothing compared to the way her views will be scrutinized going forward. Zhao, the China legal director for British pharmaceutical giant GlaxoSmithKline, was one of four company executives detained by China's Ministry of Public Security as part of a probe into whether the company funneled almost $500 million in bribes through 700 travel agencies to doctors and hospitals in order to get them to purchase or prescribe its products.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
